Sarcopenia Treatment Market Challenges, Industry Growth by 2024 Abbott Laboratories, Pfizer Inc, Novartis AG, Glaxosmithkline Plc, Nestle SA, Bayer AG, Sanofi SA, Amway

Global sarcopenia treatment market is valued approximately USD 2208.4 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 4.8% over the forecast period 2018-2025. Reduction of muscle mass considering Sarcopenia leads to loss in muscle function aligned with high changes of functional impairment, mortality and disability in the adult population. Furthermore, malnutrition is one of the emerging causes for early age sarcopenia specially in developing regions. Also changing lifestyle and physical inactivity has led to early age sarcopenia. Increasing prevalence and lack of permanent cure has led to several research and development across the disease. Further changing lifestyles has increased the impact of the disease among the adults in their early 30s. Several initiatives have been taken against the diseases. One such initiative is Canada Sarcopenia Foundation, which is dedicated to preventing and reverse the course of metabolic disease and sarcopenia.

Get Free Sample Copy of This Report@
https://www.qurateresearch.com/report/sample/HnM/QBI-BRC-HnM-344033

Top Leading Companies mentioned are Abbott Laboratories, Pfizer Inc, Novartis AG, Glaxosmithkline Plc, Nestle SA, Bayer AG, Sanofi SA, Amway

Increasing prevalence of sarcopenia across the adults at early age and the rising awareness levels of the consumers is anticipated to drive the growth in pre-sarcopenia market over the forecast period. On the basis of type the Global Sarcopenia market is segmented into Pre-Sarcopenia, Sarcopenia, Severe Sarcopenia. Currently, the market is dominated by sarcopenia market with a majority revenue share of 43.55% in 2017. Sarcopenia is getting very prevalent across the age group of 50-80 years. Severe sarcopenia is more prevalent across people of age group above 80 years. Severe sarcopenia affects both physical performance and strength which includes loss of muscle mass.

Knowledge about sarcopenia has increased during the past decade. Various epidemiological and pathophysiological aspects are better understood today than few years ago. Researchers have found that muscle pathology can cause adverse health effect and it is evident with various studies that this adverse consequence are treatable, and the effects can be delayed through certain treatment strategies. The advancement of sarcopenia treatment such as Ursolic acid is a pentaciclyc triterpenoid found in apples. This acid has the potential to reduce muscle weakness and atrophy associated aging. Ursolic acid stimulate an increase in muscle by repressing atrophy-associated skeletal muscle gene expression. These is the major factor that spur the growth of investment for drug and supplement development in Sarcopenia treatment market. The rapid increasing investment for drug and supplement development changes the nature of pricing and competition in the market are also become a reason to enhance the market growth over the coming years.

Request for more information@
https://www.qurateresearch.com/report/enquiry/HnM/QBI-BRC-HnM-344033

The regional analysis of global sarcopenia treatment market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to surging prevalence of cancer and chronic diseases. Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2018-2025 due to escalating prevalence of geriatric population and surging incidences of diabetes.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Presarcopenia
Sarcopenia
Severe Sarcopenia

By Application:
Hospitals
Clinics
Ambulatory Surgical Centers

Click Here To Get Exclusive Discount@
https://www.qurateresearch.com/report/discount/HnM/QBI-BRC-HnM-344033

By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025

Target Audience of the Global Sarcopenia Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers

Purchase this Premium Report
https://www.qurateresearch.com/report/buy/HnM/QBI-BRC-HnM-344033/

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Contact Us:
Nehal Chinoy
Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
IN +919881074592
info@qurateresearch.com
https://www.qurateresearch.com/

This release was published on openPR.